We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

CRISPR Therapeutics AG (CRSP) CHF0.03

Sell:$39.80 Buy:$43.00 Change: $0.46 (1.14%)
NASDAQ:1.35%
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$39.80
Buy:$43.00
Change: $0.46 (1.14%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$39.80
Buy:$43.00
Change: $0.46 (1.14%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Contact details

Address:
Baarerstrasse 14
ZUG
6300
Switzerland
Telephone:
+41 (41) 5613279
Website:
https://crisprtx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CRSP
ISIN:
CH0334081137
Market cap:
$3.46 billion
Shares in issue:
85.35 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Switzerland
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Samarth Kulkarni
    Chairman of the Board, Chief Executive Officer
  • Raju Prasad
    Chief Financial Officer
  • Julianne Bruno
    Chief Operating Officer
  • James Kasinger
    General Counsel, Secretary
  • Naimish Patel
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.